BAY-1251152 is a potent and highly selective PTEF/CDK9 inhibitor.

(-)-BAY-1251152, the enanthiomer of BAY-1251152 which is a potent and highly selective PTEF/CDK9 inhibitor.

CLK-IN-T3 is a novel, potent and highly selective CLK (CDC-like kinase) inhibitor with high specificity to CLK1-3 protein isoforms and with IC50s of 0.67 nM, 15 nM, and 110 nM for CLK1, CLK2, and CLK3 protein kinases, respectively.

HQ-461 is a novel Molecular-glue degrader.

THZ531 (THZ-531) is a novel, potent and irreversible / covalent inhibitor of Cyclin-dependent kinases CDK12 and CDK13 (IC50 =158 nM and 69 nM for CDK12/13, respectively) with anticancer effects.

Milciclib (formerly also known as PHA-848125; PHA-848125AC; PHA848125) is a novel, potent, ATP-competitive small molecule CDK inhibitor with potential anticancer activity.

Alsterpaullone (also known as 9-Nitropaullone and NSC-705701; NSC 705701) is a novel and potent ATP-competitive cyclin-dependent kinases (CDK) inhibitor with IC50s of 35 nM, 15 nM, 200 nM and 40 nM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E and CDK5/p35, respectively.

NU6140 is a novel and potent cyclin-dependent kinase 2 (cdk2) inhibitor.

Bohemine, structurally similar to Olomoucine and Roscovitine, is a novel, potent, selective, and cell-permeable cyclin-dependent kinase (CDK) with IC50s of 4.6, 83, and 2.7 μM for Cdk2/cyclin E, Cdk2/cyclin A, and Cdk9/cyclin T1, respectively.

Abemaciclib mesylate (formerly known as LY-2835219; LY2835219; trade name: Verzenio) is a potent and selective, orally bioavailable dual inhibitor of CDK4 (cyclin-dependent kinase) and CDK6 with potential antineoplastic activity.